🇺🇸 FDA
Patent

US 10086088

Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord

granted A61KA61K31/7088A61K38/17

Quick answer

US patent 10086088 (Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord) held by The Regents of the University of California expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/7088, A61K38/17, A61K38/177, A61K48/00